Taken together, these clinical and preclinical observations implicate SIRT2 in pathways relevant to diabetic kidney disease, supporting its potential as a nephropathy-related biomarker that complements, rather than replaces, conventional indices. The gene discussed is SIRT2; the disease is kidney disorder.